News Bristol-Myers Squibb Company Wiener Boerse

Equities

BMYS

US1101221083

Real-time Estimate Tradegate Other stock markets 12:41:37 2024-07-01 EDT			5-day change	1st Jan Change
38.48 ^EUR	-2.03%		+2.00%	-15.25%

05:21pm	Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	MT
06-27	Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	11:21am	MT
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America	03:38am	AQ
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	06-27	MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	06-26	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	06-24	AQ
Bristol Myers: accelerated approval in colorectal cancer	06-24	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	06-21	BU
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	06-21	CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	06-21	MT
US FDA approves Bristol Myers' colorectal cancer therapy	06-21	RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	06-21	MT
Bristol Myers: application validated for subcutaneous Opdivo	06-21	CF
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	06-21	BU
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	06-21	CI
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey	06-20	CI
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	06-20	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm